ArticlePloS one2022
Sarcopenia in head and neck cancer: A scoping review.
Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- From neck to abdomen: cervical (C3) muscle quantification as a surrogate to lumbar (L3) sarcopenia assessment in head and neck cancer: systematic review and meta-analysis.Skeletal radiology · 2026Pooled it
- Sarcopenia predicts postoperative complications in head and neck cancer: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Pooled it
- Developing a supportive care pathway for sarcopenia prevention in nasopharyngeal carcinoma: a context-sensitive and implementation-oriented approach.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Sarcopenia is associated with poor swallowing outcomes after resection and free flap reconstruction for oral cancer.Oral oncology reports · 2026Article
- Article
- Osteosarcopenia as a prognostic indicator of gastric cancer compared with established nutritional markers.Langenbeck's archives of surgery · 2026Article
- Automated Pretreatment Thoracic CT-Based Body Composition Analysis Predicts Progression-Free Survival in Head and Neck Cancer.Journal of clinical medicine · 2026Article
- Multimodal intervention for sarcopenia in nasopharyngeal carcinoma patients undergoing definitive treatment: a pilot randomized controlled trial protocol.Nutrition journal · 2026Article
- Muscle matters: automated CT-based body composition analysis predicts survival in patients with head and neck cancer treated with immunotherapy.Frontiers in oncology · 2026Article
- Sarcopenia-driven gene model as a clinically actionable prognostic signature for head and neck squamous cell carcinoma.Translational cancer research · 2025Article
- Article
- Physical activity in people affected by head and neck cancers: gender-specific barriers and preferences-ORLAPA survey results.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Article
- Unveiling the relation between swallowing muscle mass and skeletal muscle mass in head and neck cancer patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Nutrition in head and neck cancer care: a roadmap and call for research.The Lancet. Oncology · 2025Review
- The role of radiotherapy planning images in monitoring malnutrition and predicting prognosis in head and neck cancer patients: a pilot study.Radiation oncology (London, England) · 2025Article
- Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Impact of magnetic resonance imaging-defined sarcopenia on prognosis in patients with locally advanced nasopharyngeal carcinoma.Discover oncology · 2025Article
- Analysis of the current status of computed tomography diagnosis of sarcopenia.Archives of medical science : AMS · 2025Article
- Grip-Strength-Lean-Mass Index (GSLMI) as a valuable tool for sarcopenia diagnosis and survival prognosis in cancer patients: a nationwide multicenter cohort study.The journal of nutrition, health & aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn those undergoing treatment for head and neck cancer (HNC), sarcopenia is a strong prognostic factor for outcomes and mortality. This review identified working definitions and methods used to objectively assess sarcopenia in HNC.
methodThe scoping review was performed in accordance with Arksey and O'Malley's five-stage methodology and the Joanna Briggs Institute guidelines. INFORMATION SOURCES: Eligible studies were identified using MEDLINE, Embase, Scopus, Cochrane Library, and CINAHL databases. STUDY SELECTION: Inclusion criteria represented studies of adult HNC patients in which sarcopenia was listed as an outcome, full-text articles written in English, and empirical research studies with a quantitative design. DATA EXTRACTION: Eligible studies were assessed using a proprietary data extraction form. General information, article details and characteristics, and details related to the concept of the scoping review were extracted in an iterative process.
resultsSeventy-six studies published internationally from 2016 to 2021 on sarcopenia in HNC were included. The majority were retrospective (n = 56; 74%) and the prevalence of sarcopenia ranged from 3.8% to 78.7%. Approximately two-thirds of studies used computed tomography (CT) to assess sarcopenia. Skeletal muscle index (SMI) at the third lumbar vertebra (L3) (n = 53; 70%) was the most prevalent metric used to identify sarcopenia, followed by SMI at the third cervical vertebra (C3) (n = 4; 5%).
conclusionsCurrently, the most effective strategy to assess sarcopenia in HNC depends on several factors, including access to resources, patient and treatment characteristics, and the prognostic significance of outcomes used to represent sarcopenia. Skeletal muscle mass (SMM) measured at C3 may represent a practical, precise, and cost-effective biomarker for the detection of sarcopenia. However, combining SMM measurements at C3 with other sarcopenic parameters-including muscle strength and physical performance-may provide a more accurate risk profile for sarcopenia assessment and allow for a greater understanding of this condition in HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.